Risankizumab for crohn disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Aug 2020: Trial registered, NCT04524611
  2. 30 Sep 2020: Trial started, NCT04524611

The trials

NCT04524611: Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

State
Under way
Phase
Phase 3
People
527 taking part
Started
30 Sep 2020
Primary completion
Feb 2028
Arms
Risankizumab Dose A Followed by Dose B
Results
None posted
  1. 24 Aug 2020: Trial registered
  2. 30 Sep 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as BI-655066.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.